Advertisement

Neuronal inclusions and α-Synucleinopathy in a patient with 5p deletion syndrome

      Highlights

      • Chromosome 5p deletion (5p-) syndrome may present with neurodegenerative features.
      • 5p- pathology is variable possibly with olfactory aplasia and/or polymicrogyria.
      • 5p- pathology includes cerebral neuronal inclusions like cortical Lewy bodies.
      • 5p- pathology may show α-Synucleinopathy in the limbic and paralimbic cortex.
      • α-Synucleinopathy may be involved in the pathophysiology of 5p- syndrome.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Nguyen J.M.
        • Qualmann K.J.
        • Okashah R.
        • Reilly A.
        • Alexeyev M.F.
        • Campbell D.J.
        5p deletions: current knowledge and future directions.
        Am. J. Med. Genet. C: Semin. Med. Genet. 2015; 169: 224-238https://doi.org/10.1002/ajmg.c.31444
        • Hong J.H.
        • Lee H.Y.
        • Lim M.K.
        • Kim M.Y.
        • Kang Y.H.
        • Lee K.H.
        • Cho S.G.
        Brain stem hypoplasia associated with Cri-du-chat syndrome.
        Korean J. Radiol. 2013; 14: 960-962https://doi.org/10.3348/kjr.2013.14.6.960
        • Sharma P.
        • Gupta N.
        • Chowdhury M.R.
        • Sapra S.
        • Shukla R.
        • Lall M.
        • Kabra M.
        Inherited 5p deletion syndrome due to paternal balanced translocation: phenotypic heterogeneity due to duplication of 8q and 12p.
        J. Pediatr. Genet. 2013; 2: 163-169https://doi.org/10.3233/PGE-13062
        • Galvin J.E.
        • Lee V.M.
        • Trojanowski J.Q.
        Synucleinopathies: clinical and pathological implications.
        Arch. Neurol. 2001; 58: 186-190https://doi.org/10.1001/archneur.58.2.186
        • Shults C.W.
        Lewy bodies.
        Proc. Natl. Acad. Sci. U. S. A. 2006; 103: 1661-1668
        • Espay A.J.
        • Vizcarra J.A.
        • Marsili L.
        • Lang A.E.
        • Simon D.K.
        • Merola A.
        • Josephs K.A.
        • Fasano A.
        • Morgante F.
        • Savica R.
        • Greenamyre J.T.
        • Cambi F.
        • Yamasaki T.R.
        • Tanner C.M.
        • Gan-Or Z.
        • Litvan I.
        • Mata I.F.
        • Zabetian C.P.
        • Brundin P.
        • Fernandez H.H.
        • Standaert D.G.
        • Kauffman M.A.
        • Schwarzschild M.A.
        • Sardi S.P.
        • Sherer T.
        • Perry G.
        • Leverenz J.B.
        Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases.
        Neurology. 2019; 92: 329-337https://doi.org/10.1212/WNL.0000000000006926
        • Olanow C.W.
        • Perl D.P.
        • DeMartino G.N.
        • McNaught K.S.
        Lewy-body formation is an aggresome-related process: a hypothesis.
        Lancet Neurol. 2004; 3: 496-503https://doi.org/10.1016/S1474-4422(04)00827-0
        • Ghiglieri V.
        • Calabrese V.
        • Calabresi P.
        Alpha-Synuclein: from early synaptic dysfunction to neurodegeneration.
        Front. Neurol. 2018; 9: 295
        • Savica R.
        • Bradley B.F.
        • Mielke M.M.
        When do α-synucleinopathies start? An epidemiological timeline: a review.
        JAMA Neurol. 2018; 75: 503-509https://doi.org/10.1001/jamaneurol.2017.4243
        • Olichney J.M.
        • Murphy C.
        • Hofstetter C.R.
        • Foster K.
        • Hansen L.A.
        • Thal L.J.
        • Katzman R.
        Anosmia is very common in the Lewy body variant of Alzheimer's disease.
        J. Neurol. Neurosurg. Psychiatry. 2005; 76: 1342-1347https://doi.org/10.1136/jnnp.2003.032003
        • Jęśko H.
        • Lenkiewicz A.M.
        • Adamczyk A.
        Treatments and compositions targeting α-synuclein: a patent review (2010–2016).
        Expert Opin. Ther. Patents. 2017; 27: 427-438https://doi.org/10.1080/13543776.2017.1261112